COVID, conflicts and rising global interest rates mean dedicated emerging market bond funds have attracted zero inflows over ...

Medical-technology companies are helping revive initial public offerings in the life-sciences sector in the US after a tough year so far, during which regulatory uncertainty has hampered such activity ...